Basic information Safety Supplier Related

Cadonilimab

Basic information Safety Supplier Related

Cadonilimab Basic information

Product Name:
Cadonilimab
Synonyms:
  • Cadonilimab
  • Research Grade Cadonilimab (DHH02221)
  • Research Grade Cadonilimab
CAS:
2394841-59-7
MW:
0
Mol File:
Mol File
More
Less

Cadonilimab Chemical Properties

form 
Liquid
color 
Colorless to light yellow
More
Less

Cadonilimab Usage And Synthesis

Uses

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC)[1][2][3][4].

in vivo

Cadonilimab (3.7 MBq, tail i.v., a single dose) modified with 124I largely enriches in the spleen, tumor sites and results in enrichment of PD1/CTLA4 positive immune cells at the tumor sites in humanized mice with MC38-hPD-L1 cell xenografts[4].

Animal Model:Normal KM mice and B-hPD1/hCTLA4-MC38-hPD-L1 mice[4]
Dosage:3.7 MBq (Cadonilimab modified with 124I)
Administration:tail i.v., a single dose, 2, 24, 96 and 192?h post-injection acquired static PET scans
Result:Resulted in higher tumor to nontumor (T/NT) ratios and increaseed the standard uptake value (SUV) value at the tumor site modified with 124I in mice.

References

[1] Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel). 2021 Aug 31;14(9):884. DOI:10.3390/ph14090884
[2] Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296. DOI:10.1080/19420862.2021.2014296
[3] Chen PY, et al. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab. Front Immunol. 2023 Aug 3;14:1188523. DOI:10.3389/fimmu.2023.1188523
[4] Hou X, et al. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice. Biomed Pharmacother. 2024 Jun;175:116669. DOI:10.1016/j.biopha.2024.116669

CadonilimabSupplier

ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Email
422450190@qq.com
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
TargetMol Chemicals Inc.
Tel
15002134094
Email
marketing@targetmol.cn
Atagenix Laboratories
Tel
027-87008169 17762441161
Email
info@atagenix.com
More
Less

Cadonilimab(2394841-59-7)Related Product Information